The FDA is proposing to withdraw the liquid formulation of simvastatin, known as FloLipid, from the market after Salerno Pharmaceuticals failed to file required annual reports, according to a Nov. 18 notice in the Federal Register.
The FDA annual reports convey labeling information and technicalities, including updates on labeling and on chemistry, manufacturing and controls, according to FDA policy. The agency is giving Salerno Pharma the opportunity to request a hearing if it wants to argue why the approval should not be withdrawn.
The FDA approved FloLipid in April 2016. Salerno marketed it as the first liquid statin available in the U.S., an option for patients who have trouble swallowing pills. Generic simvastatin tablets remain widely available.
